Sagmeister M, Oec L, Gmür J
Department of Internal Medicine, the Division of Hematology, University Hospital of Zürich, Zürich, Switzerland.
Blood. 1999 May 1;93(9):3124-6.
The threshold for prophylactic platelet transfusions in patients with hypoplastic thrombopenia generally recommended in the standard literature is 20,000 platelets/microL. A more restrictive transfusion policy may be indicated in patients with chronic severe aplastic anemia (SAA) in need of long-term platelet support. We evaluated the feasibility and safety of a policy with low thresholds for prophylactic transfusions (</=5,000 platelets/microL in stable patients; 6,000 to 10,000 platelets/microL in cases with fever and/or hemorrhagic signs) combined with progressive lengthening of transfusion intervals (up to at least 7 days irrespective of the interim course of platelet counts). The study was based on a retrospective analysis of a total of 18,706 patient days with platelet counts </=10,000/microL in patients with chronic SAA treated (for more than 3 months) on an outpatient basis. Altogether, 1,135 platelet transfusions were given, 88% at counts </=10, 000/microL and 57% at counts </=5,000/microL. The mean transfusion interval was 10 days. During the period of observation, three major nonlethal bleeding complications occurred, which could be well controlled. We conclude that the restrictive policy with low transfusion thresholds and prolonged transfusion intervals proved feasible and safe in chronic SAA patients.
标准文献中普遍推荐的再生障碍性血小板减少症患者预防性血小板输注阈值为20,000个血小板/微升。对于需要长期血小板支持的慢性重型再生障碍性贫血(SAA)患者,可能需要采取更严格的输血策略。我们评估了一种低阈值预防性输血策略(稳定患者中≤5,000个血小板/微升;发热和/或有出血体征的患者中为6,000至10,000个血小板/微升)并逐步延长输血间隔时间(无论血小板计数的中间过程如何,至少延长至7天)的可行性和安全性。该研究基于对18,706个患者日的回顾性分析,这些患者为门诊治疗(超过3个月)的慢性SAA患者,血小板计数≤10,000/微升。总共进行了1,135次血小板输注,88%在计数≤10,000/微升时进行,57%在计数≤5,000/微升时进行。平均输血间隔时间为10天。在观察期间,发生了3例主要的非致命性出血并发症,但均得到了良好控制。我们得出结论,低输血阈值和延长输血间隔时间的限制性策略在慢性SAA患者中被证明是可行和安全的。